Exclusive


Wellness Pioneer Branches into Cannabis with Groundbreaking Technology Platform

August 20th, 2021 - Ryan Allway

Nature is the lifeblood of the health and wellness industry. In fact, rainforest plants account for the raw material to produce a quarter of Western pharmaceuticals, including more than 120 different drugs. The challenge is understanding natural compounds and converting them into a format that maximizes their benefits to humans. Let’s take a look at […]

Ketamine One’s KGK Science Acquisition Provides Numerous Benefits

August 19th, 2021 - Ryan Allway

  KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, […]

Cannabix Continues to Build Out Intellectual Property Portfolio for Marijuana Breathalyzer technologies 

August 19th, 2021 - Ryan Allway

The cannabis industry has experienced significant growth over the past decade thanks to shifting consumer sentiments, legislative victories, and a growing corporate sector. At the same time, governments have struggled to keep up with regulations to protect consumers—including the safety of those that aren’t consuming any cannabis. In the 1960s, alcohol breathalyzers became widely available […]

KetamineOne Applies Cutting-Edge Tech & Research to Enhance Psychedelic Therapies Across Growing Clinic Network

August 11th, 2021 - Ryan Allway

The psychedelic renaissance has taken the research community by storm, but psilocybin, DMT, MDMA, and other therapies remain in development. Ketamine is the only widely available psychedelic therapy that the FDA approves to treat depression and suicidal ideations. As a result, investors may want to start there for near-term opportunities. Let’s take a look at […]

Ketamine is Leading the Psychedelic Revolution: Here’s How to Invest

July 19th, 2021 - Ryan Allway

The FDA approval of Johnson & Johnson’s Spravato®—an esketamine nasal spray for treatment-resistant depression—marked the start of the psychedelic revolution. While ketamine was well-known as an anesthetic and party drug, the regulatory approval opened the door to treating the leading cause of disability worldwide—depression. Ketamine alleviates the symptoms of depression in a matter of hours, […]

Rising Cannabis Extractor Going Public Today

July 15th, 2021 - Robin Lefferts

In the Canadian cannabis market, Cannabis 3.0 is finally starting to realize the sales potential many investors imagined back in 2019. That is when Canada legalized cannabis-derived products like oils, extracts, and edibles, and the thought was these new products would spur incredible growth in a somewhat flat industry that hadn’t been returning profits on […]

MedXtractor’s Reference Database Sets the Stage for SHAMAN & YMI

July 13th, 2021 - Ryan Allway

Artificial intelligence is already transforming many parts of our everyday lives. For example, Netflix recommends movies we’d enjoy, Facebook identifies friends in photos, and Alexa understands voice commands. Yet, despite these recent advances, most experts agree that AI is only starting to scratch the surface of what’s possible. According to Grand View Research, the global […]

MedXtractor Fills a Key Gap in Mental Health Treatments

June 30th, 2021 - Ryan Allway

  According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. MedXtractor Corp.’s (CSE: MXT) (OTC: […]

Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy

June 21st, 2021 - Robin Lefferts

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. Every major professional sport is undergoing an analytics revolution. Pharmaceutical companies use artificial intelligence (AI) to […]

Market Share vs. Market Cap in Canadian Cannabis

June 15th, 2021 - Robin Lefferts

  The adult-use cannabis market got off to a raging start before even one gram was sold. Many companies committed vast resources to greatly increase production capacity ahead of full legalization. Many of those companies achieved lofty valuations in the public capital market as a result. After about two and a half years, a look […]

Hempsana: An Emerging Leader in Cannabis 3.0

June 15th, 2021 - Ryan Allway

  The cannabis movement began with the legalization of medical and adult-use cannabis in Canada and parts of the United States. With the Cannabis 2.0 revolution, cannabis producers expanded beyond flower to produce edibles, beverages, vapes, tinctures and other products while cannabidiol (CBD) became legal in many jurisdictions around the world. The next stage of […]

Ovation Science’s Proven Science, IP, and Royalty Model Protects Investors and the Company

June 9th, 2021 - Ryan Allway

If a company has developed very effective, transformative technology, it takes an investment into research and development and time.  It also pays to protect it from copycats and pirates with patents. And if the company’s specialty is science and product development rather than in retail sales and marketing, a royalty- or license-based revenue model could […]

Dispensaries Can Boost Cannabis Sales with Unique Topical Products

June 7th, 2021 - Robin Lefferts

  As the legal cannabis industry matures and expands, the goal of many companies is (and should be) to reach people who might not historically be cannabis consumers. According to a 2020 Gallup poll, about 12% of US adults say they smoke marijuana. This percentage has remained fairly steady over the past several years, even […]

BC’s First Craft Cannabis Hub Open to All Investors

June 4th, 2021 - Ryan Allway

British Columbia may be well-known for its legendary cannabis strains and connoisseur-level products, but licensed small-batch producers -known as ‘micro-cultivators’, have struggled to reach the same scale as licensed producers in the legal market. Many lack the resources to remain in compliance, and they are seeking service providers for quality assurance skills,  packaging, pricing  and […]

RYAH Medtech Expanding Internationally with Flurry of Deals

June 3rd, 2021 - Robin Lefferts

  A sometimes overlooked aspect of the cannabis industry is the global potential for North American companies. To be sure, the United States and Canada represent the largest and most mature legal cannabis markets, and many companies are rightfully focused on them exclusively. But some companies are set up to not only capitalize on these […]

Gage Growth Corp. Impressing Both Consumers and Analysts

June 1st, 2021 - Ryan Allway

Gage Growth Corp. (CSE: GAGE) (OTC: GAEGF) went public in early April 2021, and with a month or two under its pubco belt analysts are taking a closer look at the company. Meanwhile, Gage’s focus on the high growth Michigan legal cannabis market, premium brands covering a wide range of product types, and a clean […]

Decibel Cannabis Co. Flourishes Amid Provincial Supply Reset

May 28th, 2021 - Robin Lefferts

With financial results coming in for Q1 2021, there is a pattern emerging among Canadian Licensed Producers of cannabis. With a few exceptions, sales and revenue figures are significantly down across the board. Compared to the prior quarter, many companies are reporting sales decreased anywhere from 10% to upwards of 25% for the period. There […]

Ovation: Where Science, Medicine, and Cannabis Meet

May 28th, 2021 - Ryan Allway

  With the quickly expanding legal cannabis market finding its legs after years of prohibition, there are several hurdles remaining before the plant and its cannabis-derived product offspring are fully accepted by mainstream society. First and foremost is, of course, full legalization. From that important step everything follows, from banking regulations to changes in incarceration […]

NASDAQ-listed Enveric Acquires MagicMed to Bring Psychedelics Derivatives to Market

May 25th, 2021 - Ryan Allway

 Enveric Biosciences (NASDAQ: ENVB), best-known for its pipeline of naturally occurring cannabinoid compounds, recently entered into a definitive agreement to acquire MagicMed Industries, a private biotechnology company focused on building a library of novel derivative psychedelic molecules with applications across multiple indications. The transaction broadens Enveric Bioscience’s focus into psychedelics and complements its existing pipeline […]

Cybin Looks to Develop the Next Blockbuster Drugs

May 18th, 2021 - Ryan Allway

The pharmaceutical industry has struggled for years to develop effective psychiatric and neurological treatments. For example, many antidepressants and antipsychotics show only marginal efficacy in reducing symptoms compared to placebos over the short-term. The long-term use of many psychiatric drugs is also associated with adverse side-effects. Psychedelics are an exciting development in neuropsychiatry because of […]

2nd Annual WWC Conference: Connecting Womxn in Cannabis and Psychedelics

May 17th, 2021 - Ryan Allway

  Bridget Hoffer and Katie Pringle of the Award-winning cannabis marketing and PR firm, Marigold PR  The second annual Womxn, Wellness and Cannabis Conference will take place virtually on May 26-27, 2021. As the largest free virtual event of its kind, the WWC Conference brings together industry trailblazers in an inclusive, fun and educational online […]

True Leaf Empowers Micro-Cultivators to Usher in Craft Cannabis Era

May 14th, 2021 - Ryan Allway

Canada’s cannabis market is dominated by large cultivators and processors operating at scale. Of course, most of the industry’s largest companies are more focused on margins and volume, resulting in expensive low-to-mid quality cannabis, which could be part of the reason that the illegal market still accounts for about 60% of all cannabis sales nationwide. […]

Decibel Continues Growth in Key Products, Markets

May 14th, 2021 - Ryan Allway

The story of the cannabis industry has finally boiled down to its essence after years of hype- and story-driven investment. The fundamental question is now, as it should be: Who can sell their stuff and make money doing it? It is time for companies to show their hands, and the market decides who is bluffing. […]

Newly Public RYAH Medtech Sets Table for Expansion

May 13th, 2021 - Robin Lefferts

  RYAH Group, Inc. (CSE: RYAH) and its wholly owned subsidiary RYAH Medtech Inc. began trading publicly May 10, 2021 on the Canadian Securities Exchange. The reverse takeover was nearly two years in the making, bringing RYAH’s suite of smart cannabis and plant-based medicine devices (and the accompanying treasure trove of data) to the public […]

Newly Public Gage Cannabis on a Steep Growth Trajectory

May 11th, 2021 - Robin Lefferts

  Investors looking for value in the legal cannabis industry might be looking for some key indicators to point the way to companies of interest. Organizations operating in key and lucrative markets, showing fast revenue growth that looks like it will continue, and having experienced executives to guide the company through the various pitfalls of […]

Why Are Analysts So Bullish on Cybin?

May 6th, 2021 - Ryan Allway

The global psychedelics market is projected to grow from $4.75 billion to $10.75 billion by 2027, according to Research and Markets, representing a strong 12.36% compound annual growth rate. With more than 40 public companies in the psychedelics sector and an exchange-traded fund, there is no shortage of opportunities for investors interested in the space. […]

Patents in the Cannabis Industry: Increased Investor Protection

May 5th, 2021 - Robin Lefferts

In any emerging industry, patent protection becomes a key component. The ability to exclusively produce and profit off of one’s own innovation encourages research, development, and investment. Many companies’ valuations are based in a large part on the extent to which their intellectual property is protected. The cannabis industry offers some hurdles to achieving that […]

Fiore Posts Strong Q1 Performance as Restructuring Pays Off

April 30th, 2021 - Ryan Allway

  The cannabis industry reached US$22.9 billion in 2020, according to ReportLinker, which projects that it will grow at an 18.1% compound annual growth rate through 2026. In the U.S., the Biden administration promised to pursue cannabis decriminalization as a number of new states have moved to legalize medical and/or recreational cannabis. Fiore Cannabis Inc. […]

Invest in Cannabis Co-Manufacturing with The Galley

April 29th, 2021 - Ryan Allway

 The U.S. cannabis industry is projected to double in size to $41.5 billion by 2025, according to New Frontier Data, driven by strong consumer demand, greater spending per consumer and the legalization of cannabis in new states. While cannabis flower remains popular, concentrates, edibles and other manufactured products have opened the door to a wider […]

How to Invest in Psychedelics

April 29th, 2021 - Ryan Allway

The psychedelics industry is following in the same projectile footsteps of the cannabis industry and could be on its way to becoming a multi-billion dollar industry. With the potential to transform mental health treatments. Researchers from Johns Hopkins and other leading institutions have embraced advancements in psychedelic research which has spawned a growing list of […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading